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Abstract 
Objective: Obesity and insulin resistance play important roles in the pathogenesis of 
nonalcoholic fatty liver disease (NAFLD). Intake of magnesium is linked to a reduced 
risk of metabolic syndrome and insulin resistance, people with NAFLD or alcoholic 
liver disease are at high risk of magnesium deficiency. The purpose of this study was 
to investigate whether intakes of magnesium and calcium were associated with risk of 
fatty liver disease and prediabetes by alcohol drinking status.  
Design：We analyzed the association between calcium or magnesium intake and fatty 
liver disease, prediabetes or both prediabetes and fatty liver disease in a cross-sectional 
analysis. 
Setting: The Third National Health and Nutrition Examination Survey (NHANES Ⅲ) 
follow-up US adults cohort. 
Subjects：A nationally representative sample of US adults in NHANES including 
13,489 participants was enrolled in this study. 
Results: After adjusting for potential confounders, we found that intake of magnesium 
was associated with approximately 30% reduced odds of fatty liver disease and 
prediabetes comparing the highest intake quartile versus the lowest. Magnesium intake 
may only be related to reduced odds of fatty liver disease and prediabetes in those 
whose calcium intake was less than 1200 mg per day. Magnesium intake may also only 
be associated with reduced odds of fatty liver disease among those alcohol drinkers.  
Conclusion: This study suggests that high intake of magnesium may be associated with 
reduced risks of fatty liver disease and prediabetes. Further large studies, particularly 
prospective cohort studies, are warranted to confirm the findings.  
Key Words: magnesium, calcium, fatty liver disease, prediabetes 
Introduction 
All-cause cirrhosis and cancer of the liver are two of the four top leading causes of 
death from gastrointestinal and liver diseases in United States(1). Globally, the mortality 
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rate from cirrhosis and cirrhosis-related diseases has increased over the past 35 years(2). 
A large portion of liver cirrhosis and cancer are caused by nonalcoholic fatty liver 
disease (NAFLD), and alcoholic liver disease(3). NAFLD is the most common liver 
disease in the world(4–6), which includes a spectrum of liver injury ranging from 
steatosis to severe steatohepatitis that can progress to fibrosis, cirrhosis, liver failure, or 
even liver cancer(7). Unlike alcoholic liver disease which is caused by chronic heavy 
alcohol use, the etiology of NAFLD is not clear but may include obesity, type 2 diabetes, 
use of drugs, and exposure to toxic substances(8–10). NAFLD is considered a feature of 
metabolic syndrome(11).  
 
Magnesium may be a factor that is related to the etiology of both alcoholic liver disease 
and NAFLD. People who chronically drink heavy amounts of alcohol are at high risk 
of magnesium deficiency(12) and prolonged exposure to alcohol leads to a substantial 
reduction in magnesium homeostasis in the liver(13). Furthermore, as many as 50% of 
type 2 diabetic patients have hypomagnesaemia(14). As such, one previous study found 
serum magnesium levels were significantly lower in patients with either alcoholic or 
non-alcoholic liver steatosis(15). A meta-analysis of randomized trials indicates 
magnesium supplementation improves insulin resistance in patients with type 2 
diabetes(16). Magnesium intake has also been linked to a reduced risk of metabolic 
syndrome(17) and type 2 diabetes(18,19). Very recently, we reported that high intakes of 
magnesium may be associated with a reduced risk of mortality due to liver disease 
particularly among alcohol drinkers and those with hepatic steatosis(20).  
 
In this study, we examined whether the intake of magnesium was associated with the 
prevalence of fatty liver disease or prediabetes. Although previous studies have 
examined the association between intake of calcium and type 2 diabetes(21), few studies 
have examined the role of calcium intake in association with prediabetes(22). Our recent 
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studies indicate that calcium intake may interact with magnesium intake in relation to 
diseases of gastrointestinal tract (GI), such as colorectal adenoma(23), adenoma 
recurrence(24), reflux esophagitis, Barrett’s esophagus(25) and other chronic disease(26). 
Thus, we hypothesize that intake of calcium may also be related to risk of fatty liver 
disease and prediabetes.  
 
To test these novel hypotheses and to examine whether these associations differ by 
alcohol drinking status, we analyzed the data from the Third National Health and 
Nutrition Examination Survey (NHANE III) follow-up cohort.  
METHODS 
Study Population 
The NHANES III was conducted in the United States from 1988 through 1994 by the 
National Center for Health Statistics (NCHS) of the Centers for Disease Control and 
Prevention (CDC). The investigation was approved by the institutional review board of 
the CDC, and all participants provided informed consent. It was conducted in two 
phases, each of which comprised a national probability sample. In total, 39,695 
participants were selected from a complex multistage, stratified, clustered probability 
sample representative of the civilian, noninstitutionalized population. 33,994 (86%) 
were interviewed in their homes. All interviewed participants were invited to the mobile 
examination center (MEC) for a medical examination. In our study, we excluded 15,169 
participants younger than 20 years old. We also excluded 2,210 participants with (1) a 
physician’s diagnosis of diabetes, (2) glycolated hemoglobin (HbA1c) ≥6.5%, or (3) 
fasting glucose ≥ 126 mg/dL. 2,178 Participants did not complete dietary or 
supplemental intakes assessment, 948 participants with no information of fatty liver 
disease or prediabetes were not included in the study. As a result, 13,489 participants 
were included in the final analysis.   
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Classification of key health outcomes   
(1) Fatty liver disease: The ultrasound examination was recorded using a Toshiba 
Sonolayer SSA-90A and Toshiba video recorder among participants aged 20 to 74 years 
in NHANES Ⅲ between 1988 and 1994. In 2009-2010, archived gall bladder 
ultrasound video images were reviewed to assess the presence of fat within the hepatic 
parenchyma using standard criteria. Followed by the five criteria (liver to kidney 
contrast; brightness of the liver parenchyma; deep beam attenuation; echogenic walls 
in the small intrahepatic vessels; the definition of the gallbladder walls), hepatic 
steatosis (HS) was categorized as normal, mild, moderate, or severe. In order to avoid 
potential overlap between mild and moderate hepatic steatosis, a categorization of fatty 
liver disease as “yes” or “no” was generally used. “Yes” indicated moderate or severe 
hepatic steatosis, while “No” indicated the liver was normal or had mild hepatic 
steatosis(27).  
(2) Prediabetes cases: According to American Diabetes Association (ADA), 
prediabetes meets the following criteria: (i) no diagnosis of diabetes from a doctor, and 
(ii) fasting plasma glucose level between 100 and 125 mg/dl or HbA1c between 5.7% 
and 6.4%(28). 
(3) Both prediabetes and fatty liver disease cases: Have (1) and (2).  
(4) Controls: Those who had neither fatty liver disease nor prediabetes were regarded 
as controls.  
 
Nutrient intake assessments 
Detailed dietary and supplemental intakes including magnesium and calcium were 
derived from a single 24-hour dietary recall and a 30-day supplemental interview which 
participants completed at the examination center. For this analysis, only dietary recall 
data which was determined by NHANES to be "reliable (i.e. the individual food files 
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contain records only for participants with complete intake records that were considered 
to be reliable)” was used. The total intake of these nutrients was calculated by summing 
up the magnesium and calcium intakes from the dietary and supplemental intakes. 
Covariates  
We considered a number of factors as potential confounding factors and these include: 
age (years), sex (men and women); race and ethnicity (non-Hispanic whites, non-
Hispanic blacks, and other); educational attainment (lower than high school education, 
high school diploma, and college graduate or above); ratio of poverty to income 
(PIR:≤1, 1-3, and > 3); cigarette smoking status (never, former, and current); alcohol 
drinking status (never alcohol drinker: had less than 12 drinks of any kind of alcoholic 
beverage in entire life; former alcohol drinker: had more than 12 drinks of any kind of 
alcoholic beverage in entire life but in the past 12 months had less than 12 drinks of 
any alcoholic beverage; current alcohol drinker: had more than 12 drinks of any kind 
of alcoholic beverage in entire life and in the past 12 months had at least 12 drinks 
alcohol), physical activity status (yes: “have done one or more activities in the past 
month: jogging/running, swimming, riding a bicycle, aerobics activity, garden/yard 
work or other activity”; no: “no activity was done in the past month”), body mass index 
(BMI; kg/m2), waist to hip ratio, daily intakes of total energy (kcal/day), calcium 
(mg/day), magnesium (mg/day), use of calcium supplements (yes or no), and use of 
magnesium supplements (yes or no).   
Statistical analysis 
All analyses were performed using Survey package in SAS 9.4 software (SAS Institute, 
Cary, NC, USA) to account for the applicable weighting in the multistage clustered, 
probability sampling design in the NHANES III cohort. Covariates were compared 
between cases and controls to evaluate potential confounding factors using Rao-Scott 
chi-square test for categorical data and Survey regression models for continuous 
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variables. Survey logistic regression models with fatty liver disease or prediabetes or 
both prediabetes and fatty liver disease as the dependent variable were used to analyze 
the association between calcium or magnesium intake and fatty liver disease or 
prediabetes or both prediabetes and fatty liver disease adjusting for potential 
confounders. Total calcium or magnesium intake was included in the models as 
categorical variables, using quartiles based on the controls’ distribution. To assess the 
linear trend in the odds of calcium or magnesium quartile, the median value for each 
quartile was entered into the logistic regression model as an ordinal variable. Stratified 
analyses by gender (men or women), calcium:magnesium ratio (<2.6, ≥2.6: to be 
consistent with our previous studies, the cutpoint of 2.6 was used(24)), daily calcium 
intake (<1200 mg or ≥1200 mg), alcohol drinking status (never, former, or current 
alcohol drinker) were conducted. All reported P values were two-sided with statistical 
significance evaluated at 0.05.  
Results 
We compared demographic characteristics and potential confounding factors of cases 
with fatty liver disease, cases with prediabetes and cases with both prediabetes and fatty 
liver disease to normal controls (Table 1). Compared to controls, cases were older and 
were more likely to be men, former smokers, former alcohol drinkers, non-Hispanic 
black, and to have lower educational attainment, higher poverty, and higher BMI (body 
mass index). Cases with prediabetes consumed lower levels of calcium and magnesium 
compared to controls.  
 
After adjusting for potential confounders, we found that intake of calcium was not 
related to odds of fatty liver disease, prediabetes and both prediabetes and fatty liver 
disease. On the other hand, we found that intake of magnesium was associated with 
approximately 30% reduced odds of fatty liver disease (p for trend, 0.05) and 
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prediabetes (p for trend, 0.02). The association pattern was similar between intake of 
magnesium and risk of both prediabetes and fatty liver disease although not statistically 
significant (Table 2).  
 
In stratified analyses, we found that the intake of calcium was marginally associated 
with increased odds of fatty liver disease among women (Table 3). Also, the intake of 
calcium may be related to increased odds of prediabetes among those with a 
calcium:magnesium ratio ≥2.6, and an odds ratio (OR) of 1.98 (95% confidence interval 
=1.07-3.67) for the highest quartile intake vs. the lowest. In the stratified analysis, no 
significant association was found by drinking status (p for trend >0.05). None of the 
interactions were statistically significant.  
 
The inverse association between the intake of magnesium and risk of prediabetes was 
only significant among those with a calcium:magnesium intake ratio≥2.6 (Table 4). 
However, the p for interaction were not statistically significant (Table 4). On the other 
hand, there is a significant interaction between magnesium intake and calcium intake 
(p for interaction, 0.04) in relation to odds of prediabetes. It appears that the intake of 
magnesium may only be related to the reduced odds of fatty liver disease (p for trend, 
0.04) and prediabetes (p for trend, 0.09) when the intake of calcium < 1200 mg per day. 
In the stratified analysis according to alcohol drinking status, we found that the intake 
of magnesium may be associated with reduced odds of fatty liver disease only among 
former drinkers (p for trend, 0.04) and current drinkers (p for trend, 0.04). However, p 
for interaction was not statistically significant. We did not find the association between 
intake of magnesium and risk of fatty liver and prediabetes differed by gender. 
    
Discussion   
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In this NHANES III cohort, a nationally representative sample of the US general 
population, we found that the intake of calcium was overall not associated with the odds 
of fatty liver disease, prediabetes or both. On the other hand, we found that the higher 
intake of magnesium is significantly associated with lower odds of fatty liver disease 
and prediabetes. Due to limited sample sizes in stratified analyses, we consider the 
stratified analyses as exploratory. In the stratified analysis, the only significant 
interaction was between magnesium intake and calcium intake (p for interaction, 0.04) 
in relation to odds of prediabetes. None of the other interactions were statistically 
significant. We found that the inverse association between magnesium intake and 
prediabetes primarily appeared in those with a calcium intake <1200 mg per day; and 
in the same subgroup, intake of magnesium was also significantly related to a reduced 
odds of fatty liver disease. We also found magnesium intake was only related to reduced 
odds of fatty liver disease among former and current alcohol drinkers.  
 
Our findings of an inverse association between the intake of magnesium and 
prediabetes is consistent with that of previous studies which have shown that high 
magnesium intake is associated with a reduced risk of type II diabetes(18,29,30), metabolic 
syndrome(17,31), insulin resistance(32) and prediabetes(33). Furthermore, we found an 
inverse association between the intake of magnesium and the risk of fatty liver disease. 
This finding was not consistent with a null association found in a previous study(34). 
However, the cross-sectional study conducted in Canadians had a very small sample 
size, which may have limited the power to detect an association. We also found that the 
inverse association between the intake of magnesium and fatty liver disease primarily 
appeared in alcohol drinkers. Although novel, this finding is consistent with the 
observation that heavy alcohol drinkers are at high risk of magnesium deficiency(12). 
Future large-scale studies are needed to confirm the findings. This is important because 
previous studies have found that alcohol caused a substantial reduction in magnesium 
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homeostasis in the liver(13). It was reported by the National Health and Nutrition 
Examination Survey (NHANES), 1999–2000, that 79% of US adults do not meet the 
Recommended Dietary Allowance for magnesium(26). One study observed that serum 
concentrations of magnesium were significantly reduced in patients with either 
alcoholic or non-alcoholic liver steatosis(31).  
 
In a cohort study, the investigators found that intake of magnesium was associated with 
a reduced risk metabolic syndrome(35). Magnesium intake was also inversely associated 
with individual components of metabolic syndrome, particularly fasting glucose level, 
waist circumference, and high-density lipoprotein cholesterol. Thus, the inverse 
association between the intake of magnesium and metabolic syndrome is likely 
mediated through waist circumference or waist to hip ratio. Similarly, in our study, after 
additionally adjusting for waist to hip ratio, the significant associations disappeared. As 
such, waist to hip ratio may serve as a pathway to the relationship between magnesium 
intake and the disease outcomes (i.e. fatty liver disease and/or prediabetes) or it could 
be an over-adjustment.  
 
In the stratified analyses, we found intake of magnesium may be more significantly 
related to reduced odds of prediabetes and fatty liver disease when calcium intake was 
less than 1200 mg per day. This finding suggests that the beneficial effect of magnesium 
may be suppressed when calcium intake is higher than Dietary Reference Intakes. This 
finding is consistent with our recent finding indicating that calcium intake may interact 
with magnesium intake in relation to risks of multiple common diseases(23–26). Some(36–
38), but not all(39), previous human studies indicate that high calcium intake may affect 
the absorption rate of magnesium. It is known that over 80% of plasma magnesium is 
ultrafiltrated and reabsorbed in the kidneys. Thus, kidney reabsorption plays a key role 
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in regulating magnesium homeostasis(40). Likewise, 10 g of calcium are filtered daily 
on average, of which 98% is reabsorbed in the kidneys(41,42). Thus far, clinical trials 
consistently found that high calcium intake leads to significantly increased excretion of 
magnesium in the urine(40,43,44). Thus, it is likely that high intake of calcium may lead 
to relative deficiency of magnesium. We also found magnesium intake may only be 
associated with reduced odds of fatty liver disease among former and current drinkers. 
This finding is possible because alcohol drinkers are at high risk of magnesium 
deficiency(12). However, further large studies studies, particularly longitudinal studies 
are necessary to replicate the findings.  
   
A strength of our study is that it is based on NHANES, a population-based study with 
a nationally representative sample. However, although multiple 24-hour dietary recalls 
are used as a gold standard measure in nutritional epidemiologic studies, a one-time 24-
hour dietary recall used in the current study may not have adequately captured long-
term dietary intakes of magnesium and calcium. Since inter-day variation in intakes of 
magnesium and calcium is random, any residual inter-day variation in the current study 
would lead to non-differential misclassification, which usually biases the result to the 
null. Thus, the true association between intakes of magnesium and calcium and risk of 
prediabetes and fatty liver disease may be stronger than what we have observed. We 
cannot eliminate the possibility that the associations with intakes of magnesium and 
calcium are due to residual confounding factors or healthy lifestyle in general. However, 
we have adjusted for physical activity, and BMI as well as total energy intake. 
Furthermore, in the same analysis, we found the associations of calcium and 
magnesium are in opposite directions. Thus, it is unlikely our findings are due to 
confounding by healthy lifestyle in general because those who possess healthy 
behaviors are likely to use calcium supplements. Finally, like all cross-sectional studies, 
the temporal sequence for the associations are not clear. However, the inverse 
association between intake of magnesium and risk of prediabetes is consistent with the 
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associations between magnesium with insulin resistance(16), metabolic 
syndrome(17,31)and type 2 diabetes(18,19).   
 
 
In conclusion, our findings suggest that the high intake of magnesium may be 
associated with lower odds of having fatty liver disease and prediabetes, whereas the 
high intake of calcium was overall not related to the risk. The associations may 
primarily appear in those whose calcium intake was less than 1200 mg per day. Further 
studies, particularly prospective cohort studies, are warranted to confirm or refute the 
findings.  
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Table 1 Baseline demographic and selected risk factors by the status of disease, the Third National Health and Nutrition Examination Survey (NHANES Ⅲ) a,b 
Characteristics 
Controls 
(n=6,399) 
Fatty Liver Disease Cases  
(n=2,423) 
Prediabetes Cases 
 (n=5,818) 
Prediabetes & Fatty Liver Disease Cases 
 (n=1,511) 
Value Value p-valuec Value p-valued Value p-valuee 
Age at Screening (years), Mean (SD) 37.8 (0.4) 45.6 (0.5) <0.0001 51.3 (0.6) <0.0001 49.3 (0.7) <0.0001 
 Gender, %   <0.0001  <0.0001  <0.0001 
 Male  2625 (43.3) 1270 (54.7)  3005 (55.4)  646 (59.6)  
 Female  3774 (56.7) 1153 (45.3)  2548 (44.6)  505 (40.4)  
 Race/Ethnicity, %   0.02  <0.0001  <0.0001 
 Non-Hispanic White  2592 (78.9) 877 (75.7)  2201 (71.9)  363 (69.7)  
 Non-Hispanic Black  1737 (9.0) 525 (8.5)  1732 (14.1)  297 (11.5)  
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 Other  2070 (12.1) 1021 (15.8)  1620 (14.0)  491 (18.8)  
 Educational Attainment, %   <0.0001  <0.0001  <0.0001 
 Less Than High School Graduate  1841 (17.7) 1008 (27.3)  2330 (30.3)  524 (33.3)  
 High School Graduate 2179 (34.3) 730 (35.6)  1587 (33.9)  327 (34.7)  
 Some College or Above  2248 (48.0) 599 (37.1)  1394 (35.8)  245 (32.0)  
Income-to-poverty ratio (PIR) , %    0.04  0.001  0.02 
 ≤1 1283 (11.2) 566 (13.9)  1195 (14.0)  279 (15.0)  
 1-3  2707 (40.8) 1035 (43.2)  2324 (43.0)  493 (45.1)  
 >3  1933 (48.0) 604 (42.9)  1456 (43.0)  267 (39.9)  
 Body Mass Index (kg/m2), Mean (SD) 25.0 (0.1) 29.8 (0.3) <0.0001 27.5 (0.1) <0.0001 31.0 (0.3) <0.0001 
 Smoking status, %   <0.0001  <0.0001  <0.0001 
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 No smoker  3373 (48.3) 1127 (42.3)  2543 (41.5)  503 (37.5)  
 Former smoker  1171 (21.1) 664 (31.4)  1527 (29.3)  354 (36.8)  
 Current Smoker  1855 (30.6) 632 (26.3)  1482 (29.2)  294 (25.6)  
 Alcohol drinking status, %   0.001  <0.0001  0.0009 
 No drinker  987 (11.4) 366 (12.4)  954 (13.9)  169 (13.7)  
 Former drinker  1973 (27.7) 813 (33.3)  2074 (36.1)  431 (36.0)  
 Current drinker  3323 (61.0) 1190 (54.4)  2358 (50.0)  532 (50.4)  
Physical activity last month, yes (%) 5302 (88.4) 1857 (83.9) <0.0001 4193 (82.4) <0.0001 866 (81.1) 0.0002 
Daily nutrients intake, mean (SD)        
 Total energy (kcal)  2282.9 (25.4) 2259.5 (36.7) 0.56 2149.3 (26.0) 0.0001 2230.7 (41.6) 0.25 
 Total calcium (mg)  886.9 (14.3) 882.5 (24.7) 0.84 827.5 (16.0) 0.001 837.1 (29.7) 0.09 
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Calcium from dietary (mg)  861.9 (14.2) 858.1 (23.6) 0.86 806.4 (15.5) 0.002 817.9 (28.4) 0.12 
Calcium from supplement (mg)  175.9 (7.1) 171.0 (17.6) 0.79 172.7 (8.3) 0.76 167.7 (23.0) 0.73 
 Total magnesium (mg)  325.1 (3.8) 323.7 (6.1) 0.83 314.4 (3.1) 0.01 317.4 (7.5) 0.34 
Magnesium from dietary (mg)  309.3 (3.5) 308.5 (5.2) 0.88 300.8 (2.9) 0.04 305.5 (6.7) 0.61 
Magnesium from supplement (mg)  101.4 (5.3) 100.5 (8.7) 0.92 99.4 (3.9) 0.74 93.2 (11.2) 0.47 
Use of calcium supplements, yes (%) 905 (16.9) 286 (15.5) 0.40 749 (15.4) 0.06 143 (14.3) 0.10 
Use of magnesium supplements, yes (%) 925 (17.3) 293 (15.9) 0.39 765 (15.7) 0.04 147 (14.6) 0.10 
a Value present as unweighted frequency (weighted percentage, %) or weighted mean (SD)  
b Rao-Scott chi-square test for categorical data, and survey regression model for continuous variables 
cP value for the comparison between fatty liver disease cases and controls 
d P value for the comparison between prediabetes cases and controls 
e P value for the comparison between prediabetes & fatty liver disease cases and controls 
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Table 2 The association between intakes of calcium and magnesium with fatty liver disease, prediabetes, both prediabetes & fatty liver disease 
in NHANES 1988-1994a,b  
Daily intake (mg) 
Fatty Liver Disease vs Control Prediabetes vs Control Prediabetes & Fatty Liver Cases 
Cases/Controls ORa (95% CI) Cases/Controls ORa (95% CI) Cases/Controls ORa (95% CI) 
Calcium All subjects 
≤431 649/1600 1.00 1919/1600 1.00 335/1600 1.00 
431-690 621/1604 
0.97(0.76-1.24) 
1446/1604 
0.94(0.74-1.18) 
312/1604 
0.78(0.55-1.11) 
690-1063 616/1596 
1.18(0.90-1.54) 
1285/1596 
1.04(0.82-1.33) 
274/1596 
0.81(0.64-1.03) 
>1063 537/1599 
1.19(0.85-1.65) 
1168/1599 
1.12(0.88-1.44) 
230/1599 
0.89(0.54-1.47) 
P for trend  0.16  0.21  0.76 
Magnesium  
≤192 652/1615 1.00 1849/1615 1.00 332/1615 1.00 
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192-274 572/1600 
0.83(0.59-1.18) 
1378/1600 
0.85(0.65-1.13) 
255/1600 
0.90(0.60-1.37) 
274-383 599/1591 
0.79(0.56-1.11) 
1329/1591 
0.80(0.63-1.02) 
302/1591 
0.83(0.52-1.32) 
>383 600/1593 
0.72(0.51-1.02) 
1262/1593 
0.72(0.53-0.97) 
262/1593 
0.66(0.35-1.25) 
P for trend  0.05  0.02  0.17 
a Survey logistic regression models were used after adjusted for age, sex, race, educational attainment, household income, smoking status, alcohol 
drinking, physical activity, BMI, daily intake of total energy, magnesium or calcium, supplemental calcium intake (yes or no), supplemental 
magnesium intake (yes or no)           
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Table 3 The association between intakes of calcium with fatty liver disease, prediabetes, both fatty liver disease & prediabetes stratified by gender, 
calcium:magnesium ratio and drinking status, NHANES 1988-1994a,b  
Daily intake (mg) 
Fatty Liver Disease vs Control Prediabetes vs Control Prediabetes & Fatty Liver Disease vs Controls 
Cases/Controls ORa (95% CI) Cases/Controls ORa (95% CI) Cases/Controls ORa (95% CI) 
Calcium Men 
≤431 284/459 1.00 831/459 1.00 160/459 1.00 
431-690 301/599 0.75(0.49-1.15) 741/599 0.82(0.60-1.11) 164/599 0.59(0.35-1.01) 
690-1063 337/691 0.97(0.66-1.44) 745/691 1.01(0.72-1.41) 173/691 0.68(0.43-1.08) 
>1063 348/876 0.93(0.59-1.48) 792/876 1.12(0.80-1.56) 149/876 0.65(0.31-1.35) 
P for trend  0.77  0.19  0.46 
Calcium Women 
≤431 365/1141 1.00 1088/1141 1.00 175/1141 1.00 
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431-690 320/1005 1.17(0.77-1.78) 705/1005 1.06(0.81-1.39) 148/1005 1.10(0.73-1.65) 
690-1063 279/905 1.35(0.87-2.09) 540/905 1.04(0.78-1.40) 101/905 0.99(0.65-1.49) 
>1063 189/723 1.45(0.93-2.26) 376/723 1.02(0.76-1.36) 81/723 1.36(0.73-2.56) 
P for trend  0.06  0.91  0.48 
P for interaction  
0.79 0.25 0.52 
Calcium 
Ca:Mg ratio <2.6 
≤431 575/1361 1.00 1656/1361 1.00 297/1361 1.00 
431-690 392/1036 0.81(0.59-1.09) 912/1036 0.80(0.60-1.06) 203/1036 0.60(0.38-0.94) 
690-1063 291/662 1.05(0.74-1.49) 592/662 1.00(0.73-1.38) 144/662 0.65(0.41-1.04) 
>1063 98/264 1.59(0.87-2.90) 211/264 1.41(0.82-2.42) 38/264 0.80(0.34-1.83) 
P for trend 
 0.17  0.27  0.27 
Calcium 
Ca:Mg ratio ≥2.6 
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≤431 74/239 1.00 263/239 1.00 38/239 1.00 
431-690 229/568 1.88(0.83-4.25) 534/568 1.75(1.08-2.83) 109/568 1.75(0.78-3.94) 
690-1063 325/934 1.98(0.73-5.36) 693/934 1.70(0.90-3.22) 130/934 1.78(0.66-4.77) 
>1063 439/1335 1.90(0.62-5.76) 957/1335 1.98(1.07-3.67) 192/1335 2.53(0.72-8.97) 
  P for trend 
 0.57  0.12  0.22 
P for interaction 
0.20 0.14 0.89 
Calcium 
Never alcohol drinkers 
≤431 109/292 1.00 339/292 1.00 64/292 1.00 
431-690 98/244 1.32(0.71-2.45) 248/244 0.89(0.57-1.41) 49/244 1.28(0.47-3.49) 
690-1063 95/251 1.33(0.57-3.13) 215/251 0.74(0.48-1.14) 30/251 0.77(0.25-2.35) 
>1063 64/200 1.14(0.46-2.85) 152/200 0.88(0.49-1.59) 26/200 1.35(0.36-5.14) 
P for trend  0.73  0.46 
 
0.94 
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Calcium 
Former alcohol drinkers 
≤431 211/528 1.00 638/528 1.00 118/528 1.00 
431-690 232/511 0.94(0.73-1.20) 566/511 0.94(0.73-1.21) 133/511 1.09(0.67-1.77) 
690-1063 197/476 1.16(0.89-1.51) 454/476 1.09(0.85-1.40) 98/476 0.94(0.57-1.57) 
>1063 173/458 1.18(0.84-1.66) 416/458 1.16(0.90-1.50) 82/458 0.89(0.41-1.93) 
P for trend  0.16  0.12  0.64 
Calcium Current alcohol drinkers 
≤431 308/741 1.00 308/741 1.00 147/741 1.00 
431-690 283/822 0.82(0.56-1.20) 589/822 0.87(0.64-1.19) 127/822 0.57(0.32-1.00) 
690-1063 311/844 1.07(0.77-1.49) 577/844 1.08(0.78-1.49) 140/844 0.78(0.50-1.21) 
>1063 288/916 1.13(0.72-1.76) 567/916 1.16(0.84-1.62) 118/916 0.85(0.45-1.59) 
P for trend  0.26  0.17  0.93 
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P for interaction 0.79 0.37 0.24 
a Survey logistic regression models were used after adjusted for age, sex, race, educational attainment, household income, smoking status, alcohol drinking, 
physical activity, BMI, daily intake of total energy, magnesium, supplemental calcium intake (yes or no), supplemental magnesium intake (yes or no) 
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Table 4 The association between intakes of magnesium with fatty liver disease, prediabetes,  both fatty liver disease & prediabetes stratified by  gender, 
intake of calcium, calcium:magnesium ratio and drinking status, NHANES 1988-1994a,b  
Daily intake (mg) 
Fatty Liver Disease vs Control Prediabetes vs Control Prediabetes & Fatty Liver Disease vs Controls 
Cases/Controls ORa (95% CI) Cases/Controls ORa (95% CI) Cases/Controls ORa (95% CI) 
Magnesium Men 
≤192 234/399 1.00 702/399 1.00 130/399 1.00 
192-274 245/488 1.10(0.67-1.81) 697/488 1.04(0.66-1.64) 119/488 0.91(0.49-1.68) 
274-383 345/734 0.91(0.54-1.53) 779/734 0.76(0.53-1.10) 193/734 0.82(0.42-1.61) 
>383 446/1004 0.79(0.43-1.44) 931/1004 0.76(0.49-1.19) 204/1004 0.60(0.26-1.39) 
P for trend  0.19  0.04  0.19 
Magnesium Women 
≤192 418/1216 1.00 1147/1216 1.00 202/1216 1.00 
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192-274 327/1112 0.72(0.48-1.09) 681/1112 0.75(0.56-1.02) 136/1112 0.98(0.58-1.65) 
274-383 254/857 0.71(0.45-1.13) 550/857 0.89(0.66-1.20) 109/857 0.81(0.48-1.34) 
>383 154/589 0.72(0.42-1.25) 331/589 0.67(0.46-0.98) 58/589 0.67(0.30-1.49) 
P for trend  
0.20 
 
0.09 
 
0.25 
P for interaction 
0.88 0.22 0.10 
Magnesium 
Calcium: Magnesium <2.6 
≤192 336/771 1.00 1038/771 1.00 178/771 1.00 
192-274 306/802 0.77(0.53-1.13) 771/802 0.85(0.61-1.20) 146/802 0.81(0.48-1.37) 
274-383 344/831 0.78(0.52-1.18) 768/831 0.81(0.58-1.13) 182/831 0.77(0.42-1.40) 
>383 370/919 0.77(0.46-1.29) 794/919 0.79(0.50-1.27) 176/919 0.58(0.27-1.24) 
P for trend  
0.50 
 
0.34 
 
0.16 
Magnesium 
Calcium: Magnesium ≥2.6 
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≤192 316/844 1.00 811/844 1.00 154/844 1.00 
192-274 266/798 0.91(0.56-1.47) 607/798 0.83(0.59-1.19) 109/798 0.99(0.60-1.63) 
274-383 255/760 0.81(0.41-1.58) 561/760 0.77(0.51-1.15) 120/760 0.87(0.43-1.78) 
>383 230/674 0.69(0.36-1.32) 468/674 0.60(0.38-0.96) 86/674 0.66(0.20-2.20) 
P for trend  
0.23 
 
0.04 
 
0.46 
P for interaction  
0.25 0.14 0.29 
Magnesium Calcium intake <1200 mg/d 
≤192 648/1602 1.00 1841/1602 1.00 330/1602 1.00 
192-274 543/1498 0.75(0.53-1.08) 1305/1498 0.83(0.63-1.09) 242/1498 0.82(0.53-1.27) 
274-383 485/1272 0.70(0.50-0.99) 1091/1272 0.82(0.63-1.07) 245/1272 0.79(0.49-1.28) 
>383 341/801 0.66(0.44-0.99) 707/801 0.72(0.49-1.06) 164/801 0.66(0.33-1.30) 
P for trend  0.04  0.09  0.25 
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Magnesium Calcium intake ≥1200 mg/d 
≤192 4/13 1.00 8/13 1.00 2/13 1.00 
192-274 29/102 1.13(0.23-5.53) 73/102 2.51(0.28-22.36) 13/102 5.35(0.51-56.12) 
274-383 114/319 0.84(0.19-3.72) 238/319 1.63(0.20-13.01) 57/319 2.48(0.24-25.62) 
>383 259/792 0.87(0.19-4.07) 555/792 1.58(0.20-12.69) 98/792 2.21(0.20-24.29) 
P for trend  0.74  0.40  0.41 
P for interaction 0.69 0.04 0.34 
Magnesium Never alcohol drinker 
≤192 135/331 1.00 373/331 1.00 73/331 1.00 
192-274 99/288 1.11(0.58-2.14) 253/288 0.87(0.55-1.37) 45/288 1.02(0.37-2.80) 
274-383 80/227 0.93(0.46-1.90) 194/227 0.85(0.49-1.46) 34/227 0.86(0.37-1.99) 
>383 52/141 1.18(0.57-2.43) 134/141 0.66(0.43-1.03) 17/141 0.64(0.17-2.49) 
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P for trend  0.85  0.08  0.46 
Magnesium Former alcohol drinkers 
≤192 239/570 1.00 671/570 1.00 141/570 1.00 
192-274 190/504 0.78(0.54-1.13) 520/504 0.85(0.63-1.14) 93/504 0.97(0.47-2.02) 
274-383 212/457 0.76(0.52-1.11) 480/457 0.79(0.62-1.02) 116/457 1.03(0.55-1.95) 
>383 172/442 0.67(0.46-0.98) 403/442 0.72(0.52-1.01) 81/442 0.66(0.25-1.77) 
P for trend  0.04  0.03  0.45 
Magnesium Current alcohol drinkers 
≤192 265/672 1.00 508/672 1.00 115/672 1.00 
192-274 267/785 0.66(0.40-1.09) 559/785 0.82(0.53-1.25) 112/785 0.76(0.52-1.11) 
274-383 296/885 0.62(0.37-1.05) 615/885 0.72(0.48-1.07) 149/885 0.66(0.38-1.14) 
>383 362/981 0.58(0.36-0.94) 676/981 0.70(0.43-1.12) 156/981 0.54(0.29-1.00) 
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P for trend  0.04  0.09  0.13 
P for interaction 
0.64 
0.47 0.33 
a Survey logistic regression models were used after adjusted for age, sex, race, educational attainment, household income, smoking status, alcohol drinking, 
physical activity, BMI, daily intake of total energy, calcium, supplemental calcium intake (yes or no), supplemental magnesium intake (yes or no) 
 
